Climb Bio (CLYM) News Today $1.89 +0.09 (+5.00%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLYM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Climb Bio (NASDAQ:CLYM) Given "Sell (D-)" Rating at Weiss Ratings1 hour ago | marketbeat.comAnalysts Set Climb Bio, Inc. (NASDAQ:CLYM) Price Target at $9.25October 9 at 2:01 AM | americanbankingnews.comClimb Bio, Inc. (NASDAQ:CLYM) Sees Significant Drop in Short InterestOctober 7 at 7:59 AM | marketbeat.comClimb Bio (NASDAQ:CLYM) Upgraded by Wall Street Zen to "Hold" RatingOctober 6 at 3:38 AM | marketbeat.comClimb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from AnalystsOctober 4, 2025 | marketbeat.comClimb Bio Appoints New CFO Susan AltschullerOctober 1, 2025 | tipranks.comClimb Bio, Inc. Appoints Susan Altschuller, Ph.D., MBA, as Chief Financial OfficerOctober 1, 2025 | quiverquant.comQClimb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial OfficerOctober 1, 2025 | globenewswire.comBTIG Maintains Climb Bio (CLYM) Buy RecommendationSeptember 30, 2025 | msn.comClimb Bio price target raised to $8 from $7 at BTIGSeptember 30, 2025 | msn.comClimb Bio announces CLYM116 preclinical dataSeptember 29, 2025 | msn.comClimb Bio, Inc. Reports Promising Preclinical Data for CLYM116 in IgA Nephropathy and Plans Phase 1 Trial InitiationSeptember 29, 2025 | quiverquant.comQClimb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgANSeptember 29, 2025 | globenewswire.comClimb Bio (NASDAQ:CLYM) Cut to Sell at Wall Street ZenSeptember 28, 2025 | marketbeat.comBTIG Research Reiterates Buy Rating for Climb Bio (NASDAQ:CLYM)September 22, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Stock Rating Upgraded by Wall Street ZenSeptember 20, 2025 | marketbeat.comClimb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Buy" from BrokeragesSeptember 11, 2025 | marketbeat.comAllostery Investments LP Takes $299,000 Position in Climb Bio, Inc. $CLYMSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Buys Shares of 119,320 Climb Bio, Inc. $CLYMSeptember 5, 2025 | marketbeat.comClimb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunitySeptember 4, 2025 | msn.comRA Capital Management L.P. Makes New Investment in Climb Bio, Inc. $CLYMSeptember 4, 2025 | marketbeat.comClimb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025September 4, 2025 | globenewswire.com1,500,000 Shares in Climb Bio, Inc. $CLYM Purchased by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comUPDATE – Climb Bio to Present at Upcoming September 2025 Investor ConferencesAugust 25, 2025 | globenewswire.comClimb Bio to Present at Upcoming September 2025 Investor ConferencesAugust 25, 2025 | globenewswire.comClimb Bio (NASDAQ:CLYM) Rating Increased to Strong-Buy at Baird R WAugust 18, 2025 | marketbeat.comClimb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutionsAugust 17, 2025 | finance.yahoo.comQ3 Earnings Forecast for Climb Bio Issued By Leerink PartnrsAugust 17, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Now Covered by Robert W. BairdAugust 17, 2025 | marketbeat.comBaird Initiates Coverage of Climb Bio (CLYM) with Outperform RecommendationAugust 16, 2025 | msn.comClimb Bio initiated with an Outperform at Baird on budoprutug potentialAugust 15, 2025 | msn.comClimb Bio initiated with an Outperform at BairdAugust 14, 2025 | msn.comClimb Bio (NASDAQ:CLYM) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPSAugust 13, 2025 | marketbeat.comClimb Bio, Inc.: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 12, 2025 | finanznachrichten.deClimb Bio reports Q2 EPS (13c) vs ($1.81) last yearAugust 12, 2025 | msn.comClimb Bio, Inc. Advances Clinical Trials for Budoprutug in ITP and SLE, with Upcoming Initiation of pMN Trial and CLYM116 Webcast EventAugust 12, 2025 | quiverquant.comQClimb Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 12, 2025 | globenewswire.comClimb Bio (CLYM) Expected to Announce Quarterly Earnings on WednesdayAugust 7, 2025 | marketbeat.comClimb Bio Inc (CLYM) - Yahoo FinanceAugust 5, 2025 | finance.yahoo.comPeapod Lane Capital LLC Buys New Shares in Climb Bio, Inc. (NASDAQ:CLYM)July 10, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Trading Down 4% - Should You Sell?July 2, 2025 | marketbeat.comClimb Bio appoints Edgar D. Charles as Chief Medical OfficerJune 18, 2025 | msn.comClimb Bio Appoints Cindy Driscoll as Finance VPJune 18, 2025 | tipranks.comOppenheimer Initiates Coverage of Climb Bio (CLYM) with Outperform RecommendationJune 7, 2025 | msn.comClimb Bio (NASDAQ:CLYM) Earns Outperform Rating from Analysts at OppenheimerJune 6, 2025 | marketbeat.comCLYM Climb Bio, Inc.May 30, 2025 | seekingalpha.comClimb Bio (NASDAQ:CLYM) Coverage Initiated at BTIG ResearchMay 24, 2025 | marketbeat.comBTIG sets Climb Bio stock Buy rating, $7 targetMay 23, 2025 | investing.comClimb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | finanznachrichten.deWhat is Leerink Partnrs' Estimate for Climb Bio Q2 Earnings?May 20, 2025 | marketbeat.com Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLYM Media Mentions By Week CLYM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLYM News Sentiment▼0.950.77▲Average Medical News Sentiment CLYM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLYM Articles This Week▼52▲CLYM Articles Average Week Get the Latest News and Ratings for CLYM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Climb Bio and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Organogenesis News Today Prothena News Today CytomX Therapeutics News Today Ocugen News Today Eton Pharmaceuticals News Today Corvus Pharmaceuticals News Today Zevra Therapeutics News Today REGENXBIO News Today Inhibrx Biosciences News Today Fulcrum Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLYM) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
